The Silent Epidemic: How India’s Pharmaceutical Pipeline is Fueling West Africa’s Opioid Crisis
Across West Africa, from Accra to Lagos, from Lomé to Ouagadougou, tens of thousands of people are trapped in addiction to synthetic opioids whose supply chain runs through India, through West African ports, and into the hands of vulnerable communities with disturbingly little international attention.
France 24’s investigation in early May 2026 confirmed that over 320 million units of unapproved synthetic drugs — primarily tapentadol and tramadol formulations — have been exported to West Africa from India over recent years, facilitated by trade data that shows more than 1,400 shipments of tapentadol alone. These are not medicines in any meaningful sense. They are industrial-scale opioid shipments targeting one of the world’s most underserved pharmaceutical regulatory environments.
The Drug That Rewrote a City
In Sierra Leone, a substance locally called kush arrived in the early 2020s and spread with extraordinary speed. By 2024, health workers in Freetown were describing it as the most serious substance abuse crisis the country had ever faced. The drug is typically cheaper than alcohol, widely available in urban informal settlements, and devastating in its effects.
What makes kush particularly alarming is its composition. Unlike traditional opioids, which have predictable potency, kush is mixed ad hoc by dealers using whatever synthetics are available. Fentanyl analogues — up to 100 times more potent than morphine — appear inconsistently and unpredictably, dramatically increasing the risk of fatal overdose.
India’s Role: Regulatory Failure or Calculated Export?
India’s pharmaceutical industry is one of the world’s largest and most capable, producing generic medicines that have saved millions of lives globally. The question of how a legitimate industry became a major source of illegal opioid exports to West Africa is contested.
A more troubling interpretation, advanced by UNODC researchers, is that the export pipeline has been knowingly managed by firms that have learned they face little enforcement risk as long as shipments technically comply with minimal documentation requirements. The volume involved — 320 million units — makes regulatory ignorance at source implausible.
The Community Response
Across West Africa, communities are not waiting for governments or international bodies to act. In Sierra Leone, President Julius Maada Bio launched the Hastings Rehabilitation Centre and, in October 2025, addressed the nation on the crisis. By April 2026, 47 Mental Health Champions had been inducted as part of a grassroots outreach programme.
In Ghana and Togo, faith-based and civil society organisations have established community support groups modelled on addiction recovery programmes, though their reach is severely limited by funding and training constraints.
The International Response Gap
The West African opioid crisis exposes a profound asymmetry in global drug policy. When opioid addiction surged in North America and Europe in the 2010s, it generated massive public health responses and billions in treatment funding. When an equivalent epidemic has taken hold in West Africa, the response has been negligible.
The UNODC World Drug Report 2025 addresses synthetic opioids but concentrates almost exclusively on North American and European markets. West Africa appears primarily as a transit region — a framing that has allowed the crisis to develop largely beneath the radar of global health institutions.
Sources: France 24, UNODC World Drug Report 2025, BBC News Investigation, Sierra Leone Ministry of Health, Social Science in Action
